^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Thymic Carcinoma |
| Drug: | erfonrilimab (KN046) (PD-L1 inhibitor, CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2186P - KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
Published date:
10/16/2023
Excerpt:
Among the PD-L1-positive patients, the ORR and PFS were numerically higher than that in PD-L1 negative or status unknown, which was 18.8% vs. 14.8% in ORR and 7.6 months vs 5.6 months in PFS...KN046 demonstrated promising antitumor activity and acceptable toxicity in thymic carcinoma patients who have received at least one line of chemotherapy.
Trial ID:
